scPharmaceuticals Inc.

NASDAQ: SCPH · Real-Time Price · USD
4.83
-0.12 (-2.42%)
At close: Aug 15, 2025, 12:04 PM
-2.42%
Bid 4.82
Market Cap 257.31M
Revenue (ttm) 41.98M
Net Income (ttm) -90.78M
EPS (ttm) -1.81
PE Ratio (ttm) -2.67
Forward PE -15.93
Analyst Buy
Ask 4.84
Volume 53,914
Avg. Volume (20D) 394,672
Open 4.98
Previous Close 4.95
Day's Range 4.79 - 5.00
52-Week Range 1.94 - 6.28
Beta 0.39

About SCPH

undefined

Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SCPH
Website n/a
Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SCPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

scPharmaceuticals has released their quartely earnings on Aug 7, 2025:
  • Revenue of $16.04M exceeds estimates by $232.96K, with 99.17% YoY growth.
  • EPS of -0.34 misses estimates by -0.04, with 22.73% YoY growth.
  • Next Earnings Release

    scPharmaceuticals Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    +28.57%
    scPharmaceuticals shares are trading higher after ... Unlock content with Pro Subscription
    5 months ago
    -1.89%
    scPharmaceuticals shares are trading higher after the company announced FDA approval for a supplemental new drug application expanding the FUROSCIX indication to include the treatment of edema in patients with chronic kidney disease.